Next Phase Newsletter

The Corporate Venture Fund is a $50 million venture fund established by the parent company, an insurance company. The focus of the initiative is to develop a portfolio of investments that, as a whole, focus on improving the health care market, enhance the core business of the company and generate revenue. These strategic investments are expected to be integrated into the company as part of its overall long-term strategy. The firm prefers to syndicate with a strong lead investor in a financing round and expects to make 5 – 7 new investments of $0.5-2 million in the coming year. The firm considers opportunities across the US and around the world with preference given to companies in the middle of the country.

The fund is interested in digital health technologies and care delivery models that can improve healthcare. The firm prefers products with prototype and customer traction.

The fund would like to be a strategic partner, as a payer, for startups. The firm prefers early stage teams backed by experienced management, supported by reputable early stage VC and/or angel groups that have a history of follow-on investments in Series A and B.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A newly established venture capital firm founded in 2020 and is based in Barcelona, Spain. The firm is currently raising its first fund targeting €30M, and expects to close in mid to late 2021 and become fully operative. The firm is actively seeking investment opportunities and performing due diligence on companies they identify as a fit with the firm. The firm’s focus is in Seed to Series A financings and initial size of investment will be around €500K, and can invest up to €2.5M over the life of investment. The firm is open to USA-based opportunities but will focus on those based in Europe, Israel, and Spain where the firm is based.

The firm is exclusively interested in companies in the longevity space. In this regard, the firm is most interested in digital technologies including AI, robotics, data analytics, etc. Traditional therapeutics or devices do not fall within their investment priority, as the firm prefers to seek opportunities that leverage digital technologies to deliver novel therapeutic solutions (i.e. digital therapeutics). The firm is open to very early-stage, pre-revenue technologies and are open to university spin-offs/tech transfers.

The firm is backed by co-founders who have entrepreneurial backgrounds and can be a hands-on investor, assisting with company creation and other support as needed. When investing in companies that are not in geographical proximity to the firm, the firm prefers to co-invest alongside larger VC firms.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A Venture Capital firm based in CA invests in companies in Consumer, Enterprise, as well as Life Science & Digital Health. For companies in the life sciences, the firm generally invests in Series seed/A/B rounds, committing between $1-10M in capital. The firm is willing to invest in both the US and China, and will consider companies in pre-clinical and clinical development.

Within the life sciences, the firm is willing to invest in therapeutics, diagnostics, medtech, digital health and R&D services. For therapeutics, the firm will consider traditional therapeutics that are first-in-class, either a novel target or novel therapeutic, but is agnostic to indication. For diagnostics, medtech, digital health and R&D services, the firm focuses on AI-based technologies. Previous investments include AI-based drug discovery platforms, pathology screening, diagnostic services and care management platforms.

The firm looks for companies with a strong management team, large market opportunity and a disruptive technology. When investing, the firm is willing lead or co-invest, and will occasionally take a board seat after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A newly established venture capital firm founded in 2020 and is based in Palo Alto, CA. The firm’s first fund recently had its first close at $25M, and is actively seeking early-stage investment opportunities in life sciences and healthcare sectors. The firm is focused on emerging companies in pre-seed / seed rounds and will participate in Series A at the maximum. Currently, the firm is focused on USA-based companies, but can dedicate up to 20% of their fund to invest outside of the USA.

The firm invests in 4 main focus areas, ordered by priority: (1) biotech (40%), which includes biomarkers, liquid biopsies, cell therapy, smart packaging, drug delivery, next generation sequencing, omics; (2) digital health (30%), which includes wearables, diagnostics, services, AI-enabled approaches, management, fitness, digital therapy; (3) medtech (20%), which includes smart devices, smart lens, breath biopsy, 3D printing, in vitro diagnostics, surgical robotics, laser therapy; (4) health edtech (10%), which includes personalized learning, med. professional development, immersive learnings (e.g., VR), wellness. The firm plans to expand their investment capabilities in medtech, as they have recently made great investments in this space. The firm is indication agnostic, and is open to all opportunities including oncology, cardiovascular, infectious, metabolic, neurological, and rare/orphan diseases.

The firm seeks to work with companies backed by a management team with deep domain expertise and technologies that are backed by solid IP. The firm prefers to act as a follow-on, but will seek to lead more investment rounds in the future.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

An early-stage healthcare venture fund with teams based in USA and Asia looks to invest in visionary teams and cutting-edge technologies in both life science and digital health solutions.

The firm’s philosophy is not to take a one-size-fits-all approach to investing. The firm draws from their domain expertise and diversified experiences across the full healthcare spectrum to cover both Biopharma and Digital Health sectors. The firm’s aim is to support companies that can achieve differentiated therapeutic results through truly novel approaches. Combining scientific rigor and strategic connections within our network, the firm provides guidance and add value to our portfolio companies as they grow. The firm is seeking to work with companies from late Seed to Series B, and is open to global opportunities.

The firm is focused on two main investment themes:

(1) Life Sciences – the firm looks for sound scientific principles and seek innovative approaches, including breakthrough medicines and platform technologies. The firm’s key areas of interest include neurological diseases, metabolic diseases, and infectious diseases. The firm’s investment team engages with entrepreneurs and companies from early pre-clinical development where there is compelling science with cell and/or animal model proof of concept data and invests through pre-clinical and early clinical proof of concept stages;

(2) Digital Health / Bio IT

Digital health is a transformational area in healthcare. The firm looks for technology platforms that enable pertinent scientific insights into drug development and design or enhanced delivery of care from providers to patients. Key areas of interest include synthetic biology, machine learning for drug discovery (proteomics and metabolomics), and tools that help reduce healthcare costs.

The firm is looking for experienced management teams with strong scientific expertise and management skills.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A publicly traded company focused on oncology therapeutics is seeking therapeutic opportunities in the oncology space. The firm is looking to partner and collaborate as well as in-license, but is primarily seeking partnerships. The firm seeks assets that have at the very least cellular proof of concept, but prefers companies to have some animal data or are approaching pre-IND studies. The firm is also willing to partner with unique and differentiated drug discovery platform companies. The firm will partner globally, but primarily partners with US and Europe-based companies.

The firm is interested only in oncology and immuno-oncology assets in high unmet tumor indications including RCC and HCC. For modality, the firm is interested only in small molecule and biologics. The firm is willing to consider therapeutics targeting both solid and liquid tumors. The firm will also partner with drug discovery companies, such as those using AI-based technologies to identify new therapeutic biology, as well as platform companies.

The firm will only partner with companies that have a strong IP position and a clear differentiating discovery and development strategy. The firm looks for startups with unique “First-in-Class” therapeutics and platforms.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm based in USA and Asia with limited partners including institutional investors from US and China, typically invests $5-10M in businesses from Series A to pre-IPO and public traded companies. The firm is open to leading or following a syndicated round. The firm is now seeking opportunities in North America.

The firm invests across therapeutics, medical devices, diagnostics, platform technologies, and healthcare IT and is looking for companies that are top 3 in their niche sector. Within therapeutics, the firm prefer clinical stage projects. The firm is opportunistic in terms of disease areas including orphan indications. Within device and diagnostics, the firm prefers post-prototype products with clinical validation.

The firm may request board representation or board observer ship on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.